The White House is weighing an executive order that would place a politically appointed commission in charge of reviewing and possibly vetoing grants from the National Institutes of Health (NIH). Senate Appropriations Committee Chair Susan Collins (R-Maine) and Vice-Chair Patty Murray (D-Wash.) have publicly urged the administration to abandon the proposal, arguing that it would subvert a system built on peer-review and scientific merit.
Collins addressed a letter to Office of Management and Budget Director Russ Vought and NIH Director Jay Bhattacharya warning that an outside panel would turn grant decisions into a political litmus test. The senators stress that NIH funding is meant to serve patients and families waiting for breakthroughs, not the agenda of any single office.
Congressional leaders warn White House on NIH grant control
In a joint statement, Collins and Murray warned that the proposed commission would “undermine the NIH procedure of awarding research money based on scientific and merit-based review.” Murray emphasized, “Whether lifesaving medical research gets funded or not should be determined by experts at the NIH, not a panel of lackeys chosen by Donald Trump and Russ Vought.” She added, “NIH funding doesn’t belong to Donald Trump. It belongs to the patients and families waiting on the next medical breakthrough.”
Collins and Murray cite scientific merit as core principle
Collins echoed the same sentiment, noting that the NIH has historically funded a broad spectrum of fundamental research—even when immediate public benefit is not obvious. She warned that politicizing the process could jeopardize long-term studies on chronic disease prevention, autism, nutrition improvement, and other areas the administration claims to prioritize. The senators argue that the agency’s internal review already filters projects through rigorous, expert-driven criteria, making an extra political layer redundant and risky.
Administration’s push extends beyond NIH, raising alarms across agencies
The controversy mirrors recent moves by the Trump administration in other scientific arenas. The Environmental Protection Agency recently cancelled $27 billion in grants from the Greenhouse Gas Reduction Fund, cutting programs for clean energy, emissions reduction and environmental technology. Simultaneously, the National Science Foundation dismantled most of the $386 million Ocean Observatories Initiative, a network of more than 900 ocean sensors that gathers data on marine ecosystems, climate and extreme weather.
Democrats have also accused the Department of Defense of attempting to siphon NIH research dollars for military purposes. Health and Human Services officials countered that the NIH and the Defense Department are merely “exploring opportunities for collaboration,” but critics worry that such language could mask an expanding political footprint in biomedical science.
What’s at stake for patients and research
Representative Rosa DeLauro (D-Conn.) warned that “Funding for life-saving biomedical research should never, ever be subject to political litmus tests.” She highlighted ongoing studies into cancer, Alzheimer’s disease and heart disease that could lose momentum if grant decisions become politicized. NIH spokesperson Joshua Pradko reassured the public that the agency “remains committed to its mission of funding biomedical research to benefit the health of the American people” and affirmed, “There will be no rescissions to NIH grant monies. All NIH grant monies will be spent.”
While the White House has not yet released a finalized executive order, the mounting pressure from both parties suggests a prolonged tug-of-war over who ultimately decides how billions of dollars in federal scientific research are allocated. The outcome will determine whether the NIH can continue to operate as a bastion of independent, merit-driven science or become another instrument of partisan policy.
